XVIPF (Xvivo Perfusion AB) Momentum Rank: 10 (As of Jul. 04, 2026) — 233% Above Median


XVIPF Xvivo Perfusion AB XVIPF
91 GF Score
Price $29.00
GF Value $43.65
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Momentum Rank?

Xvivo Perfusion AB XVIPF -1.32% 91 Momentum Rank is 10 as of Jul. 04, 2026, which is 233% above its 10-year median of 3.00. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $43.65 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Xvivo Perfusion AB has the Momentum Rank of 10.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Xvivo Perfusion AB Momentum Rank Related Terms

XVIPF vs ABT, SYK, MDT: Momentum Rank Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xvivo Perfusion AB Momentum Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Momentum Rank falls into.


XVIPF
91GF Score
Xvivo Perfusion AB XVIPF
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 10 mean?
Xvivo Perfusion AB (XVIPF) has a Momentum Rank of 10 as of Jul. 04, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Xvivo Perfusion AB and its competitors. This is 233% above median its historical median of 3.00. Over the past decade, Xvivo Perfusion AB's Momentum Rank has ranged from 1.00 to 10.00.
Is Xvivo Perfusion AB's Momentum Rank too high?
Xvivo Perfusion AB's current Momentum Rank of 10 is 233% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Momentum Rank compare to ABT and SYK?
Xvivo Perfusion AB's Momentum Rank of 10 can be compared against companies in the Medical Devices & Instruments industry. Historically, Xvivo Perfusion AB's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Medical Devices & Instruments company?
A good Momentum Rank depends on the Medical Devices & Instruments industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Momentum Rank is 10, which is 233% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $43.65, compared to a current price of $29.00 — trading 33.6% below its estimated fair value. The current Momentum Rank is 10, which is 233% above median its 10-year median of 3.00. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Momentum Rank is 10 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 33.6% below its estimated GF Value™ of $43.65. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • Momentum Rank: 10 (233% above median its 10-year median of 3.00)
  • GF Value™: $43.65 vs. price of $29.00 (33.6% below fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score

Get the complete analysis for XVIPF

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$43.65
GF Value